Reference Article: Editorial | The Hindu – Conditional ease: on the Central Drugs Standard Control Organization guidelines
UPSC Relevance:
GS Paper II – Governance and Regulation (Regulatory reforms, Ease of Doing Business, Public health governance)
GS Paper III – Science and Technology / Internal Security (Drug regulation, Consumer safety, Regulatory institutions)
The Central Drugs Standard Control Organization (CDSCO) has issued new guidelines to operationalise the compounding of minor offences under the Drugs and Cosmetics Act, 1940. This follows amendments introduced through the Jan Vishwas Act, 2023, which sought to decriminalise technical and low-risk violations to improve ease of doing business while reducing unnecessary litigation.
What the New Framework Changes
- Minor or technical violations can now be settled through compounding instead of criminal prosecution
- Firms may voluntarily disclose offences and apply to pay a fine
- Upon compounding, firms receive immunity from prosecution for that specific offence
- The scope of compoundable offences has expanded under Section 32B, excluding serious cases such as spurious or adulterated drugs
Potential Benefits
- Prevents needless criminalisation for paperwork or disclosure-related lapses
- Frees regulatory capacity to focus on serious public health violations
- Reduces litigation burden on courts and firms
- Aligns enforcement with proportionality and regulatory efficiency
Key Risks and Concerns
- Risk of the regime degenerating into a “pay and pass” system
- Excessive regulatory discretion without transparency may erode public trust
- Absence of mandatory publication of compounding orders limits public scrutiny
- No formal role for consumer groups or whistle-blowers in the process
- Broad drafting of compoundable offences may cover substantive compliance failures
- Low or inconsistently applied fines could weaken deterrence
Need for Strong Safeguards
- Public disclosure (even in redacted form) of compounding decisions
- Auditable records to detect repeat offenders
- Linking compounding to corrective and preventive actions
- Follow-up inspections and, where necessary, recalls or public alerts
- Clear distinction between technical lapses and safety-related violations
Conclusion
Compounding minor drug violations is a sensible reform if implemented with transparency, proportional penalties and strong follow-up. Without these safeguards, however, it risks undermining regulatory credibility and public health protection rather than strengthening them.
Sample UPSC Mains Question
“Decriminalisation of minor regulatory offences must balance ease of doing business with public interest.” Examine this statement in the context of the CDSCO’s new compounding guidelines under the Drugs and Cosmetics Act.